NAION Management and Prognosis in GLP-1 Drug Users For high-risk patients using GLP-1 drugs, close monitoring is essential
The leading hypothesis is that the glucagon component is involved, since GLP-1/GIP-only drugs like Mounjaro havent reported it at similar rates
For mothers navigating the complex intersection of GLP-1 therapy and breastfeeding, having access to comprehensive, up-to-date research, dosage calculators , and protocol guidance can make the difference between informed confidence and anxious guessing
hypertension, type 2 DM, dyslipidemia) A meta-analysis of 22 trials involving over 17,000 patients determined that 50.2% and 17.5% of patients treated with GLP-1RAs (exenatide, semaglutide & liraglutide) experienced a weight loss of 5% and 10% compared to placebo, and that patients without type 2 diabetes achieved a significantly greater weight loss compared to those with diabetes (Vosoughi et al, 2022)
527 Conclusions and perspective Primarily recognized for their role in diabetes mellitus treatment, GLP-1RAs have demonstrated significant benefits in cardiovascular health, skeletal muscle-related diseases, obesity management, and neurodegenerative conditions, among others
